Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Daniel V Araujo"'
Autor:
David Goldstein, Anna Spreafico, Ilan Weinreb, Trevor J. Pugh, Scott V Bratman, Bayardo Perez-Ordonez, Aaron R Hansen, Lillian Siu, Antony Tin, Alexey Aleshin, Amy Prawira, Jonathan Irish, John de Almeida, Douglas Chepeha, Stephen Smith, Marc Oliva, Daniel V Araujo, J. Javier Diaz-Mejia, Peter Olson, Tina Shek, Andrew Hope, Dax Torti, Jeffrey P. Bruce, Ben X. Wang, Anthony Fortuna, Hirak Der-Torossian, Ronald Shazer, Nickolas Attanasio, Qingyan Au, Jordan Feeney, Himanshu Sethi, Isan Chen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Externí odkaz:
https://doaj.org/article/0c91b22ec6d04b31bb0d153a425dbaed
Autor:
Iza Andrade de A. Souza, Beatriz de M. Dobbert, Barbara G. Sao Jose, Joao Pedro Homse-Netto, Larissa L. Furlan, Maira S. Abreu, Camila Ferrari, Bruno Uchoa, Kathia Abdallah, Stephano N. Lucio, Joao A. Soler, Fabio L.C. Fernandez, Luiza Ferreira, Joao D. Guedes, Aline F. Fares, Daniel V. Araujo
Publikováno v:
JCO Global Oncology, Iss 10 (2024)
PURPOSEMounting data suggest that lower doses of anti-PD(L)1 agents can be as efficacious as label-approved doses at a fraction of its cost. We compare the outcomes of patients treated with low-dose (LD) and with conventional-dose (CD) anti-PD(L)1 ag
Externí odkaz:
https://doaj.org/article/b1d064690de94f7a891e06ea352b2951
Publikováno v:
Genome Medicine, Vol 11, Iss 1, Pp 1-4 (2019)
Editorial summary Circulating tumor (ct) DNA is a powerful tool that can be used to track cancer beyond a single snapshot in space and time. It has potential applications in detecting minimal residual disease and predicting relapse, in selecting pati
Externí odkaz:
https://doaj.org/article/09c316e74865439da27cc801ea3305be
Publikováno v:
Med. 3:445-449
Patient-centered trials are pivotal to advancing the oncology field efficiently. However, in recent years, there has been a shift away from patient-centered approaches. In this commentary, we describe common non-patient-centric practices of contempor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30ba23c24782cdf61beffda394fac0c1
https://doi.org/10.1016/j.medj.2022.06.007
https://doi.org/10.1016/j.medj.2022.06.007
Autor:
Enrique Sanz-Garcia, Sofia Genta, Xiaoxi Chen, Qiuxiang Ou, Daniel V. Araujo, Albiruni R. Abdul Razak, Aaron R. Hansen, Anna Spreafico, Hua Bao, Xue Wu, Lillian L. Siu, Philippe L. Bedard
Publikováno v:
JCO Precision Oncology.
PURPOSE To evaluate early circulating tumor DNA (ctDNA) kinetics using a tumor-naïve assay and correlate it with clinical outcomes in early phase immunotherapy (IO) trials. METHODS Plasma samples were analyzed using a 425-gene next-generation sequen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82344f85a5bbd54673238a0f143703a9
https://doi.org/10.1200/po.22.00509
https://doi.org/10.1200/po.22.00509
Publikováno v:
Targeted Oncology. 17:253-270
Early clinical trials investigating antiPD(L)-1 agents rarely reached a maximum tolerated dose (MTD), and efficacy signals were observed even at the lowest dose levels. Most extended treatment intervals investigated indicated that these drugs do not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d13b916fdd3837a85e779caad4376b82
https://doi.org/10.1007/s11523-022-00890-1
https://doi.org/10.1007/s11523-022-00890-1
Autor:
Abdulazeez Salawu, Alberto Hernando-Calvo, Rachel Y. Chen, Daniel V. Araujo, Marc Oliva, Zhihui A. Liu, Lillian L. Siu
Background: Phase 1 immuno-oncology (IO) trials frequently involve pharmacodynamic (PD) biomarker assessments involving tumour biopsies and/or blood collection, with increasing use of molecular imaging. PD biomarkers are set to play a fundamental rol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::039b89fa820a189d2cd527e0a2e24b35
http://hdl.handle.net/2445/191340
http://hdl.handle.net/2445/191340
Autor:
Alberto Hernando-Calvo, Abdulazeez Salawu, Rachel Y. Chen, Daniel V. Araujo, Marc Oliva, Zhihui Amy Liu, Lillian L. Siu
Publikováno v:
European journal of cancer (Oxford, England : 1990). 175
Despite the increased number of novel immunotherapy (IO) agents under current development, their toxicity profile remains to be fully elucidated.An IO risk stratification model was developed based on 5 different variables: treatment-related deaths; r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4a04768f39c028a0fd8e4cee0d4df41
https://pubmed.ncbi.nlm.nih.gov/36084619
https://pubmed.ncbi.nlm.nih.gov/36084619
Autor:
Maira Abreu, Larissa Furlan, Yutong Ma, Hanlin Chen, Carla Ferreira, Aline Fares, Eduardo Constantino, Gustavo R. Nora, Gabriela Lucio, Tatiana Colombo, Rui Liu, Xue Wu, Qiuxiang Ou, Daniel V. Araujo
Publikováno v:
Cancer Research. 83:P6-01
Background: Locally advanced ER+/HER2- breast cancer (LABC) is an aggressive condition often requiring multidisciplinary management. While early and metastatic breast cancer are well characterized, LABC is largely underrepresented in clinical trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b14e95ff9f7b483aa1d17426f6f4bce8
https://doi.org/10.1158/1538-7445.sabcs22-p6-01-14
https://doi.org/10.1158/1538-7445.sabcs22-p6-01-14
Autor:
Thiago P. Muniz, Daniel V. Araujo, Kerry J. Savage, Tina Cheng, Moumita Saha, Xinni Song, Sabrina Gill, Jose G. Monzon, Debjani Grenier, Sofia Genta, Michael J. Allen, Diana P. Arteaga, Samuel D. Saibil, Marcus O. Butler, Anna Spreafico, David Hogg
Publikováno v:
Cancers; Volume 14; Issue 1; Pages: 89
Cancers, Vol 14, Iss 89, p 89 (2022)
Cancers
Cancers, Vol 14, Iss 89, p 89 (2022)
Cancers
Simple Summary Immune checkpoint inhibitor-induced insulin-dependent diabetes mellitus (ICI-induced IDDM) is an emerging form of autoimmune diabetes. We describe the characteristics of 34 patients who developed ICI-induced IDDM across five Canadian c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::733bce196f51d78e1c57aa00a4b62979